May 27th-28th, 2021丨Shanghai China,
In recent years, the Chinese pharmaceutical market has maintained rapid and stable growth. Driven by policies and industries, the digitalization of pharmaceuticals has been significantly improved, and traditional medicines are moving forward to digitalization. The COVID-19 has also brought new opportunities for the digitalization of pharma industry. In the past ten years of large-scale application of digital technology, many pharmaceutical companies have carried out multi-modal exploration in digitalization. However, due to the limitations of technical means and insufficient motivation, many pharmaceutical companies have never completed digital transformation. How to further strengthen the construction of digital medicine, improve the level of intelligent manufacturing, and realize the digital transformation of the entire industry chain of research and development, production, compliance, marketing, and circulation is the goal of all pharmaceutical companies.